Search
Interviews with the world’s key opinion leaders in cancer

ShowAudio Journal of Oncology

Maria-Victoria-Mateos Episode 104

María-Victoria  Mateos; ASH 2025: Unprecedented Survival Benefits with BCMA/CD3 Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma: Majestec-3 Study Findings

María-Victoria  Mateos; ASH 2025: Unprecedented Survival Benefits with BCMA/CD3 Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma: Majestec-3 Study Findings An interview with: María-Victoria  Mateos MD PhD...